Key Highlights
- Shares of Capricor Therapeutics (CAPR) climbed following the presentation of extended Phase 3 trial results for deramiocel, a treatment candidate for Duchenne muscular dystrophy, at the World Muscle Society conference in Hiroshima.
- Extended trial data revealed that 82 out of 106 participants in the HOPE-3 study completed 24 months of follow-up, with findings incorporated into the firm’s regulatory submission.
- The therapy previously achieved its primary objective at the 12-month mark, demonstrating a 54% reduction in upper-limb function decline compared to control groups.
- In July, an FDA advisory panel delivered a 9-3 vote against supporting the treatment’s cardiomyopathy indication, while showing greater receptiveness to the upper-limb efficacy data.
- The company awaits a regulatory determination from the FDA, scheduled for November 22 under the PDUFA deadline.
Capricor Therapeutics stock experienced upward movement in extended trading hours Tuesday following the disclosure of extended-duration data for deramiocel, the company’s investigational therapy for Duchenne muscular dystrophy. The information emerged through electronic posters presented at the World Muscle Society’s 31st Annual Congress taking place in Hiroshima, Japan.
Capricor Therapeutics, Inc., CAPR
The release timing carries significance. The biotech firm is awaiting regulatory clearance from the FDA for deramiocel, with November 22 serving as the target action date. The newly presented findings represent more than routine scientific updates—they form part of a substantial amendment submitted to the company’s Biologics License Application, indicating that regulatory authorities are actively reviewing this information.
The scientific poster encompasses patient data from both the Phase 3 HOPE-3 trial and its subsequent open-label extension study. Among the 106 participants initially enrolled and randomized, 82 reached the two-year milestone. This cohort consisted of 40 individuals who received deramiocel from study initiation and 42 who initially received placebo.
Insights from the Delayed-Start Trial Architecture
The study employed a delayed-start framework. Participants received either the active treatment or placebo during the initial 12-month period. Subsequently, qualifying participants gained access to the open-label extension phase, where they began receiving deramiocel irrespective of their initial treatment assignment.
This methodology enables scientists to evaluate outcomes between early-treatment and delayed-treatment groups. It addresses critical questions regarding whether initiating therapy earlier provides sustained advantages, and whether participants switching from placebo demonstrate altered disease progression patterns. The poster additionally compares two-year outcomes against natural history databases, offering an additional benchmark for typical disease progression patterns.
These extended-duration findings expand upon the initial 12-month HOPE-3 outcomes. That study achieved its primary efficacy measure, demonstrating a 54% reduction in upper-limb functional decline versus placebo on the Performance of the Upper Limb 2.0 assessment tool. The statistical significance registered at p=0.03. The Lancet published these results in July.
Regulatory Challenges and Advisory Committee Feedback
The path toward regulatory approval has encountered obstacles. In July, an FDA advisory committee delivered a 9-3 vote indicating that available evidence failed to substantiate deramiocel’s effectiveness specifically for cardiomyopathy management in the Duchenne patient population.
However, that vote addressed a limited scope. It exclusively evaluated the cardiomyopathy indication rather than the therapy’s comprehensive risk-benefit assessment, and committee members expressed more favorable perspectives when discussing the upper-limb efficacy data from HOPE-3. The FDA maintains discretion to diverge from advisory committee recommendations.
Capricor is simultaneously leveraging the WMS congress to present earlier-stage research initiatives. A poster scheduled for Wednesday presentation details the company’s StealthX exosome technology platform, designed to deliver micro-dystrophin as a redosable therapeutic approach for Duchenne. An additional Friday poster explores a comparable delivery strategy targeting Pompe disease.
Both programs remain in preclinical development stages, positioning them years away from potential regulatory submissions. They provide stakeholders visibility into Capricor’s development pipeline extending beyond the deramiocel program.
Additional scientific presentations are planned throughout the week. Craig McDonald from UC Davis is scheduled to deliver an oral presentation on October 3 examining HOPE-3 evidence addressing both skeletal muscle and cardiac endpoints.
Capricor has committed to publishing presentation materials and posters on its corporate website following each session’s conclusion. The company maintains a market capitalization near $498 million and currently operates without commercial product revenue, depending on financing activities and collaborative agreements including its Japanese partnership with Nippon Shinyaku.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
